Evogene Ltd 6-K, filed Feb 12, 2025
Evogene Ltd. (EVGN)
6-K
2025-02-12
For: 2025-02-12
View Original
Added on
April 05, 2026
About this 6-K
Evogene Ltd filed this 6-K on February 12, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission File Number 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street, Park Rehovot, Rehovot
7638517, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Evogene Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved the proposal brought before the
special general meeting of shareholders held on February 12, 2025 (following a one-week adjournment from the original meeting date) (the “Meeting”),
by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company’s articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company’s Report of Foreign
Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (“SEC”), on December 30, 2024, and sent in connection with the
Meeting.
The contents of this Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) is incorporated by reference in the registration statements on Form F-3 (SEC File No.
333-277565), and Form S-8 (SEC File Nos.
333-193788, 333-201443, 333-203856 and 333-259215) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded
by documents or reports subsequently filed or furnished.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: February 12, 2025 |
EVOGENE LTD.
(Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer |
|||